CHMP recommends Ilaris (Novartis) for treatment of Acute Gouty Arthritis
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of llaris (canakinumab, ACZ885) from Novartis, in the treatment of patients with acute Gouty Arthritis who suffer frequent attacks, and whose symptoms cannot or should not be managed with current treatment options.
Ilaris is the only available fully human monoclonal antibody that specifically targets IL-1 beta and, when approved, will offer patients suffering gouty arthritis attacks rapid pain relief via a single subcutaneous injection of 150 mg.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.